A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

802

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment-resistant Depression

Interventions

DRUG: Esketamine (Intranasal Spray)
DRUG: Duloxetine (Oral Antidepressant)
DRUG: Escitalopram (Oral Antidepressant)
DRUG: Sertraline (Oral Antidepressant)
DRUG: Venlafaxine Extended Release (XR) (Oral Antidepressant)

Sponsor

Janssen Research & Development, LLC